Alnylam Pharmaceuticals
ALNY
291 hedge funds and large institutions have $9.06B invested in Alnylam Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 110 increasing their positions, 88 reducing their positions, and 28 closing their positions.
57% more call options, than puts
Call options by funds: $82.4M | Put options by funds: $52.5M
36% more capital invested
Capital invested by funds: $6.68B → $9.06B (+$2.37B)
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
25% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 28
25% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 88
2% more funds holding
Funds holding: 284 → 291 (+7)
0.41% less ownership
Funds ownership: 91.58% → 91.17% (-0.41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$78.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$66.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$64.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.8M |
| 5 |
MC
Maverick Capital
Dallas,
Texas
|
+$34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$43.7M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$21.7M |
| 3 |
PA
Perceptive Advisors
New York
|
-$18.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.1M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$15.4M |
ALNY Hedge Fund Activity: Q1 2019 in Review
291 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2019, worth a combined $9.06B — up 36% from $6.68B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ALNY positions and 28 closed out — a net gain of 7 holders — while 110 added to existing stakes and 88 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $78.4M. The largest seller was Camber Capital Management, exiting entirely with an estimated $43.7M sold.
- 291 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2019, up from 284 in Q4 2018.
- Funds reported $9.06B of Alnylam Pharmaceuticals stock for Q1 2019, up 36% quarter-over-quarter.
- 35 funds opened new Alnylam Pharmaceuticals positions in Q1 2019 and 28 closed out, a net change of +7 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2019 was Baillie Gifford & Co, an estimated $78.4M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2019 was Camber Capital Management, an estimated $43.7M sold.
Based on aggregated 13F filings for Q1 2019.